Losartan HCTZ Medication Recalled for Elevated AZIDO Impurity
RemedyRepack Inc. is recalling Losartan HCTZ 50/12.5 mg tablets due to elevated AZIDO impurity levels exceeding acceptable manufacturing standards. The recalled product was distributed to Florida.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard involves elevated AZIDO impurity levels in a pharmaceutical product exceeding acceptable manufacturing standards, representing a documented risk of harm even though no actual injury has been reported. This meets the criterion for High severity: a risk-of-harm product where injury has not yet been reported.
Plain-English summary
RemedyRepack Inc. is recalling Losartan HCTZ 50/12.5 mg tablets in 90-count bottles. The recall affects 22 bottles with lot numbers B1377711-100521 and B1412137-102621, both expiring October 31, 2022. The original product NDC is 33342-0050-10, and the repackaged product NDC is 70518-3231-00.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations, with AZIDO impurity levels detected above acceptable limits in the affected batches.
The recalled product was distributed to Florida.
The recalled product
- Product
- Losartan HCTZ 50/12.5 mg, 90 count bottle Original NDC# 33342-0050-10 Repackaged NDC# 70518-3231-00
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug
- Hazard
- azido-impurity
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot # B1377711-100521
- exp. date 10/31/2022 B1412137-102621
- exp. date 10/31/2022
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01